Live Analyst Rating Changes 16810 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Leah R. Cann
BROO

Leah R. Cann

Brookline Capital Markets
Wall Street Analyst
★★★☆☆
#1347
on 13Foresight · ranked by our own returns
56%
Success Rate
+12.9%
Average Return
10 of 18 calls profitable · -7.0% vs benchmark
S&P 500 (SPY)
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 56% of Leah R. Cann's ratings turned a profit when each position was held for 1 year — averaging +12.9% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

2 Buy 0 Hold 0 Sell
Leah's Stock Coverage 19 ratings · 2026-08-01
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
CCCC
C4 Therapeutics
 Feb 23, 2026 BUY Strong Buy
+412.2% avg upside
19 analysts
$30.00
752.19% Upside
 +52.6% ·
MRNA
Moderna
 Sep 23, 2025 BUY Sell
+28.3% avg upside
38 analysts
$198.00
243.91% Upside
 +117.4% ·
KYMR
Kymera Therapeutics
 Jul 07, 2025 BUY Strong Buy
-0.1% avg upside
37 analysts
$65.00
37.65% Downside
 +172.2% ·
CRSP
Crispr Therapeutics AG
 Jun 26, 2025 BUY Strong Buy
+56.8% avg upside
41 analysts
 — +17.6% ·
XFOR
X4 Pharmaceuticals
 Mar 25, 2025 BUY Strong Buy
+504.7% avg upside
16 analysts
$120.00
2976.97% Upside
 -47.4% ·
MRKR
Marker Therapeutics
 Feb 10, 2025 BUY Strong Buy
+1187.0% avg upside
9 analysts
$4.00
236.22% Upside
 -9.9% ·
KURA
Kura Oncology
 Jan 06, 2025 BUY Strong Buy
+197.4% avg upside
26 analysts
$40.00
342.05% Upside
 +12.1% ·
CRBU
Caribou Biosciences
 Jan 06, 2025 BUY Strong Buy
+668.3% avg upside
12 analysts
$34.00
2252.85% Upside
 -8.5% ·
EXEL
Exelixis
 Dec 23, 2024 BUY Strong Buy
-19.1% avg upside
34 analysts
$40.00
25.91% Downside
 +39.2% ·
SYRS
Syros Pharmaceuticals
 Nov 12, 2024 HOLD Buy
+11749900.0% avg upside
9 analysts
 — · ·
LITS
Lite Strategy
 Jul 22, 2024 HOLD Buy
+1030.0% avg upside
13 analysts
 — +97.7% ·
NTLA
Intellia Therapeutics
 Jun 26, 2024 BUY Strong Buy
+260.2% avg upside
37 analysts
$24.00
122.70% Upside
 -58.1% ·
SQZB
SQZ Biotechnologies
 Nov 14, 2023 HOLD Buy
+102677.8% avg upside
7 analysts
 — -41.0% ·
VRDN
Viridian Therapeutics
 Jul 21, 2020 BUY Strong Buy
+85.7% avg upside
32 analysts
$90.00
369.99% Upside
 +1.6% ·
VSTM
Verastem
 Dec 31, 2018 HOLD Strong Buy
+160.5% avg upside
24 analysts
 — -60.1% ·
CTMX
CytomX Therapeutics
 Dec 31, 2018 HOLD Strong Buy
+251.4% avg upside
21 analysts
 — -45.0% ·
AMGN
Amgen
 Dec 04, 2018 BUY Buy
-22.0% avg upside
57 analysts
$224.00
41.46% Downside
 +21.9% ·
EDIT
Editas Medicine
 Dec 04, 2018 HOLD Buy
+429.3% avg upside
33 analysts
 — +0.9% ·
AGIO
Agios Pharma
 Dec 03, 2018 HOLD Strong Buy
+101.6% avg upside
29 analysts
 — -31.2% ·
🔒 14 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Leah R. Cann — Frequently Asked Questions
How accurate are Leah R. Cann's stock ratings?
Based on the calls 13Foresight could measure, about 56% of Leah's ratings were profitable over a one-year hold, with an average return of +13.3% per rating, or +25.6% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Leah ranked on 13Foresight?
Leah R. Cann is currently ranked #1347 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Leah cover?
Leah most recently has ratings on CCCC, MRNA, KYMR, CRSP, XFOR, MRKR, KURA, CRBU, EXEL, SYRS, LITS, NTLA and 7 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.